| Species |
Human |
| Protein Construction |
FGF10 (Gln38-Ser208)
Accession # O15520 |
|
| Purity |
> 90% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 0.1EU per μg by the LAL method. |
| Biological Activity |
FGF10, Human immobilized on CM5 Chip can bind Human FGFR2 beta (IIIb), hFc Tag in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
19.3 kDa |
| Apparent Molecular Weight |
The protein migrates to 25 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM Tris, 150mM NaCl (pH 8.0). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Fibroblast growth factor 10 (FGF10) regulates multiple stages of structural lung morphogenesis, cellular differentiation, and the response to injury. As a driver of lung airway branching morphogenesis, FGF10 signaling defects during development lead to neonatal lung disease. Lung diseases impact patients across the lifespan, from infants in the first minutes of life through the aged population. Congenital abnormalities of lung structure can cause lung disease at birth or make adults more susceptible to chronic disease. |
| Synonyms |
FGF-10; KGF2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
